CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.485
+0.535 (+0.601%)
At close: 4:00PM EDT

89.410 -0.07 (-0.08%)
After hours: 5:03PM EDT

Stock chart is not supported by your current browser
Previous Close88.950
Open89.240
Bid89.350 x 200
Ask89.480 x 800
Day's Range88.710 - 90.030
52 Week Range84.250 - 147.170
Volume3,382,337
Avg. Volume7,504,682
Market Cap67.308B
Beta1.31
PE Ratio (TTM)24.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble
    Yahoo Finance Video4 days ago

    MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: These are the top risks CEOs are citing this earnings season
    Yahoo Finance Video7 days ago

    MARKETS: These are the top risks CEOs are citing this earnings season

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: Welcome to the low volume, low liquidity algo-driven market
    Yahoo Finance Video13 days ago

    MARKETS: Welcome to the low volume, low liquidity algo-driven market

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • After headline drug flops in trials, Peninsula biotech sheds 70% of its value
    American City Business Journals1 hour ago

    After headline drug flops in trials, Peninsula biotech sheds 70% of its value

    The South San Francisco company halted development of a drug for a rare protein-misfolding condition that causes heart problems, resulting in a $534 million drop in market value.

  • Investopedia12 hours ago

    Biotech Stocks Face a Steep Drop

    An analysis of Biotech ETF XBI's chart suggests the sector could be set for a decline of over 8%.

  • 2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
    Motley Foolyesterday

    2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line

    New treatments could be coming from Celgene and bluebird bio that reshape how we treat this life-threatening gene disorder.

  • Top Research Reports for IBM, McDonald's & Gilead
    Zacks4 days ago

    Top Research Reports for IBM, McDonald's & Gilead

    Top Research Reports for IBM, McDonald's & Gilead

  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realist4 days ago

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
    Market Realist4 days ago

    Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.

  • Moody's5 days ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realist5 days ago

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...

  • What Analysts Recommend for Gilead Sciences in April 2018
    Market Realist5 days ago

    What Analysts Recommend for Gilead Sciences in April 2018

    In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.

  • Investopedia5 days ago

    Why Big Biotech Stocks May Get An Earnings Boost

    Big Bounce: Big biotech stocks may surge on better-than-expected quarterly results

  • ETF Trends5 days ago

    Big Biotech ETF Can Bounce Back

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...

  • Risankizumab Could Be AbbVie’s Long-Term Growth Driver
    Market Realist6 days ago

    Risankizumab Could Be AbbVie’s Long-Term Growth Driver

    In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.

  • Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets
    Motley Fool6 days ago

    Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets

    One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.

  • Is bluebird bio, Inc. a Buy on the Dip?
    Motley Fool8 days ago

    Is bluebird bio, Inc. a Buy on the Dip?

    Biotech stocks can be awfully risky. Find out if this one's worth the anxiety.

  • These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years
    Motley Fool10 days ago

    These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years

    Find out how these three put up huge gains while their peers struggled.

  • InvestorPlace11 days ago

    Wait for a Pullback Before Rolling the Dice on SPPI Stock

    Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) again finds itself in the news after a successful drug trial. Spectrum is engaged in drug development, licensing agreements and work with other pharma companies. Its six currently approved drugs fight diseases such as cancer.

  • TheStreet.com11 days ago

    U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

    The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

  • Otezla: Shoring Up Celgene’s Top Line
    Market Realist11 days ago

    Otezla: Shoring Up Celgene’s Top Line

    Celgene Corporation (CELG) is an integrated global biopharmaceutical company focused on innovative therapies for treating cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation. Celgene’s Otezla is an oral small molecule inhibitor of PDE4. Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in the United States, Japan, the European Union, and other international markets.

  • Novartis Enters Agreement to Acquire AveXis
    Market Realist12 days ago

    Novartis Enters Agreement to Acquire AveXis

    On April 9, 2018, Novartis AG (NVS) announced that it had entered into an agreement to acquire AveXis (AVXS), a clinical-stage gene therapy company, for ~$8.7 billion. 

  • This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous
    Motley Fool12 days ago

    This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous

    There's a new kid on the CAR-T block.

  • Celgene Stock Performance in 1Q18
    Market Realist13 days ago

    Celgene Stock Performance in 1Q18

    Celgene (CELG) is one of the leading biopharmaceutical companies, with headquarters in New Jersey. Celgene’s product portfolio includes drugs for the treatment of cancer and inflammatory diseases.

  • Agios Pharmaceuticals Shares Rise on Buyout Speculation
    Zacks13 days ago

    Agios Pharmaceuticals Shares Rise on Buyout Speculation

    Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.